Study Design Summary: Multicenter study examining TAX vs placebo in 4 week all cause mortality in adult trauma patients of both blunt and penetrating trauma. Had some interesting secondary endpoints of need for surgery and blood transfusion units given.
Notes: Fairly large study of roughly 20,000 patients, equally balanced TXA and placebo groups. The primary end point of all cause mortality at 4 weeks was significantly lower in the TXA group (14.5% vs 16.0%), with no symptoms higher in the TXA group (14.7% vs 13.3%). There was similar risk of VTE in TXA vs placebo (1.7% vs 2.0%). The median amount of blood product transfused between the two groups was equal at 3 units.
TXA given after 3 hours didn’t reduce mortality compared to placebo and thus the 3 hour mark is the current inflection point for TXA administration.
Study Conclusion: TXA reduced risk of death in trauma patients.
Fusion Beat Bottom Line Impression: TXA should be given to bleeding trauma patients within 3 hours of injury to significantly reduce risk of death.
A Fusion Beat 